Neuraminidase, from C. perfringens Inhibitors

Chemical inhibitors of neuraminidase from Clostridium perfringens include a range of compounds that target the enzyme's active site, which is crucial for its function in cleaving sialic acid residues. Oseltamivir operates by mimicking the transition state of neuraminidase's sialic acid substrate, effectively blocking the enzyme's ability to process and release progeny virions. Zanamivir, similar in action, structurally resembles the transition state during the cleavage of sialic acid, thus preventing the enzyme from performing its role. Peramivir and Laninamivir both interact with the active site of neuraminidase. Peramivir mimics the structure of sialic acid in its cleaved state to hinder the enzyme's function, while Laninamivir binds to the active site, reducing its activity and impeding the release of viral particles.

Furthermore, DANA, a sialic acid analogs, exerts its inhibitory effects by occupying the active site of neuraminidase, preventing the cleavage of sialic acid residues from host glycoproteins or glycolipids The active metabolite of Oseltamivir, Oseltamivir carboxylate, engages the active site of neuraminidase to block its function. Siastatin B and Fluorosialic acid also inhibit neuraminidase by binding to its active site; Siastatin B blocks the cleavage of glycosidic linkages of sialic acids, while Fluorosialic acid, another sialic acid analog, prevents enzyme activity by occupying the active site. Pentagalloyl glucose binds to neuraminidase, inducing conformational changes that result in loss of enzymatic activity, thereby inhibiting the release and spread of bacterial components. Each of these chemicals selectively targets neuraminidase, effectively inhibiting its function by engaging directly with the enzyme's active site and mimicking or blocking its natural substrate, sialic acid.